Invention Application
- Patent Title: ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE
-
Application No.: US15623866Application Date: 2017-06-15
-
Publication No.: US20180127406A1Publication Date: 2018-05-10
- Inventor: Alberto ORTEGA MUÑOZ , Matthew Colin Thor FYEE , Marc MARTINELL PEDEMONTE , Iñigo TIRAPU FERNANDEZ DE LA CUESTA , Maria de los Ángeles ESTIARTE MARTINEZ
- Applicant: Oryzon Genomics S.A.
- Priority: EP10171342.8 20100729; EP11160728.9 20110331; EP11160731.3 20110331; EP11160738.8 20110331
- Main IPC: C07D417/12
- IPC: C07D417/12 ; A61K31/422 ; C07D213/73 ; A61K31/433 ; C07D285/08 ; C07D285/135 ; C07D413/12 ; C07D401/12 ; C07D285/12 ; C07D277/40 ; C07D271/113 ; C07D271/07 ; C07D263/48 ; C07D261/14 ; C07D253/07 ; C07D241/20 ; C07D239/42 ; C07D237/20 ; A61K31/4245
Abstract:
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
Public/Granted literature
- US10233178B2 Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use Public/Granted day:2019-03-19
Information query
